Based on the established anti-inflammatory and cardioprotective effects attributed to APOM, we sought to determine whether reduced plasma levels of APOM may be associated with increased susceptibility to major adverse cardiovascular events (MACE) in patients with CKD. The gene discussed is APOM; the disease is chronic kidney disease.